Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

Key points in the PR/CC:

1) LF trial start will trigger NVS option exercise in Q2
2) Enough cash until end of 2019
3) Announcement of new pipeline developemnt beyond Emricasan later in 2017
4) LF trial will focus not only on decompensated patients with MELD score at or above 15 (the subset where it showed significant MELD score reduction in ph2a). This trial is the only existing trial on this very sick population who face either a transplant (only a few have access) or death
5) LF ph2b trial could either be used as base for ph3 with clinical endpoints or for AA using surrogate endpoint(s, ie MELD score). By adding 4&5 good chance of an AA then